|
Invited Talks and Plenaries
|
|
|
|
Nolan D. Human immunodeficiency virus infection, antiretroviral therapy and the mitochondrion Mitochondria 2001, February 24, 2001 to March 04, 2001. San Diego, California USA.
|
|
Mallal SA. The role of antiretroviral therapy in the development of lipodystrophy HIV treatment 2000: Clinical Management Issues, November 30, 2000 to December 03, 2000. Tucson, Arizona USA.
|
|
John M. Lipodystrophy syndrome in the Western Australian HIV Cohort Study Workshop on HIV-associated lipodystrophy syndrome, December 06, 2000 to December 09, 2000. Schloss Rheinhartshausen, Germany.
|
|
John M. Long term anti-retroviral toxicities - risk factors and management GSK Satellite Symposium, Sixth International Congress on AIDS in Asia and the Pacific (ICAAP), October 04, 2001 to October 07, 2001. Melbourne, Australia.
|
|
James IR. Presidential Address:How big is my cyclone, and other statistical tales 15th Australian Statistical Conference, July 03, 2000 to July 07, 2000. Adelaide, Australia.
|
|
Mallal SA. Long-term toxicity of antiretroviral therapy XIII International AIDS Conference, Meet the Experts Session, July 09, 2000 to July 14, 2000. Durban, South Africa.
|
|
Mallal SA. What are the relative contributions of NRTIs and protease inhibitors to lipodystrophy? 4th International Conference on Nutrition and HIV infection, 2nd European Workshop on Lipodystrophy, April 19, 2000 to April 21, 2000. Cannes, France.
|
|
Mallal SA. Symposium: The Future of Toxicogenomics in Antimicrobial Drug Development and Approval. "The toxicogenomics of abacavir hypersensitivity" 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, September 14, 2003 to September 17, 2003. Chicago, Illinois USA.
|
|
Mallal SA. A CME Symposium: Therapeutic Challenges, Enhanced Clinical Expectations: Evolution of the Protease Inhibitor Class. “Managing Regimen Difficulties: Meeting the Challenge of Safety and Tolerability” 2nd IAS Conference on HIV Pathogenesis, July 13, 2002 to July 16, 2002. Paris, France.
|
|
John M. HLA optimisation of HIV vaccine design HVTN Group Meeting. Seattle, Washington USA.
|
|
John M. Genetic Factors in ART Toxicity GlaxoSmithKline HIV Education Meeting. Noosa, Queensland Australia.
|
|
Nolan D. General Susceptibility to Drug Hypersensitivity From Toxicogenomics and Pharmacogenomics Abacavir to Nevirapine Sponsored by Boehringer, June 24, 2004 to June 25, 2004. New York, USA.
|
|
Mallal SA. HIV mutational escape from CTL responses and antiretrovirals: parallels and differences 2nd IAS Conference on HIV Pathogenesis and Treatment, July 13, 2002 to July 16, 2002. Paris, France.
|
|
Mallal SA. HIV and Hepatitis C adaptation to HLA-restricted immune responses 2004 International Meeting of the Institute of Human Virology, October 31, 2004 to November 04, 2004. Baltimore, USA.
|
|
John M. HIV adaptation a novel population-base approach Annual Conference of the Australian Society of Microbiology, September 26, 2004 to October 01, 2004. Sydney, Australia.
|
|
Mallal SA. Vaccine Development: Can Host HLA Diversity be Exploited to Overcome the Problems of HIV Diversity? International AIDS Vaccine Conference, September 18, 2003 to September 21, 2003. New York, USA.
|
|
John M. Mechanisms of Evolution of HIV-Implications for Vaccine Design International AIDS Vaccine Conference, September 18, 2003 to September 21, 2003. New York, USA.
|
|
Mallal S. How NRTIs and PIs may interact to cause the various manifestations of the lipodystrophy syndrome The Australian Health and Medical Research Congress, November 25, 2002 to November 29, 2002. Melbourne, Australia.
|
|
Mallal S. HIV adaptation to HLA-restricted immune responses at a population level- implications for vaccine design The Australian Health & Medical Research Congress, November 25, 2002 to November 29, 2002. Melbourne, Australia.
|
|
Mallal S. Antiretroviral-induced mitochondrial toxicity, including hyperlactatemia and lactic acidosis Sixth International Congress on Drug Therapy in HIV Infection, November 17, 2002 to November 21, 2002. Glasgow, UK.
|
|
Mallal S. Long-term complications of ART HIV Treatment 2002: management in the 3rd decade, November 14, 2002 to November 17, 2002. Phoenix, Arizona USA.
|
|
McKinnon E, Fusco J, Fusco G, John M, James I, Mallal S. Virological response to HAART in the CHORUS cohort GSK Observational HIV Cohorts meeting, November 06, 2002 to November 07, 2002. Boston, Washington USA.
|
|
John M, Moore C, James I, Mallal S. Immune escape mutations in HIV-1 at a population level GSK Observational HIV Cohorts meeting, November 06, 2002 to November 07, 2002. Boston, Washington USA.
|
|
Christiansen F. Immunogenetics of Drug Hypersensitivity. Plenary session 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, September 22, 2002 to September 25, 2002. San Diego, California USA.
|
|
Nolan D . Interactions between NRTI and PI therapy in lipodystrophy pathogenesis 3rd European Workshop on Lipodystrophy and Metabolic Disorders, April 25, 2002 to April 27, 2002. Marbella, Spain.
|
|
John M . Antiretroviral simplification for tolerability reasons British HIV Association (BHIVA) meeting, April 19, 2002 to April 21, 2002. York, United Kingdom.
|
|
John M. Convolution profiles of responses to first HAART Observational HIV Cohorts meeting (GlaxoSmithKline), December 06, 2001 to December 08, 2001. Washington, USA.
|
|
John M. Lactic acidosis-clinical observations Lipodystrophy Workshop, January 23, 2001 to January 24, 2001. Clivedon House, Berkshire, United Kingdom.
|
|
Nolan DA, Mallal SA, John M. Developing the tools for investigating mitochondrial toxicity in a clinical setting Mitochondrial toxicity meeting. Forum for Collaborative HIV Research. Washington, USA.
|
|
Mallal SA. Metabolic complications of ART: Clinical manifestations Glaxo Wellcome HIV Speakers Program 2000, April 14, 2000 to April 15, 2000. New Orleans, Louisiana USA.
|
|
Mallal S. Vaccine development - can the problems of HIV and HLA diversity be overcome? Workshop on Pathogen Genomics and Infectious Diseases in Africa, March 19, 2003 to March 22, 2003. Capetown, South Africa.
|
|
Mallal S. Adaptations of HIV to the immune system 15th Challenge in Virology, Swiss Academic Foundation for Education in Infectious Diseases, January 14, 2005. Saanen-Gstaad, Switzerland.
|
|
Mallal S. HIV adaptation: genetic hurdle, selective advantage and replicative cost Emerging concepts in Antiretroviral Therapy, Centre for AIDS Research, University of California San Francisco, Gladstone Institute of Virology and Imm, January 12, 2005. San Francisco, California USA.
|
|
Mallal S. HIV and HCV adaptation to HLA-restricted responses , January 10, 2005. Vancouver, Canada.
|
|
Mallal S. Abacavir hypersensitivity as a model for elucidating class-I-restricted drug reactions Canadian HIV Advisory Group Meeting, October 22, 2004. Montreal, Canada.
|
|
Mallal SA. Human immunodeficiency virus and hepatitis C adaptation to HLA restricted immune responses 16th Australian Society for HIV Medicine Conference, September 04, 2004. Canberra, Australia.
|
|
Mallal SA. How can we apply understanding of host-pathogen genetic interactions to the search for an effective HIV vaccine? Human Genetics Society of Australasia ASM, Oral O12, August 11, 2004. Fremantle, Western Australia.
|
|
Mallal S. HIV adaptation to HLA restricted responses at an individual and population level Co-Chair of Mini Symposium: "HIV and Immunity", 12th International Congress of Immunology and 4th Annual Conference on FOCIS, July 23, 2004. Montreal, Canada.
|
|
Nolan D. Contributions of Antiretroviral Drugs to Lipodystrophy Sponsored by Abbott Pharmaceuticals, July 19, 2004. Athens, Greece.
|
|
Mallal SA. Plensary Session: HLA imprinting: Implications for selection of vaccine immunogens. Plenary session Session 15, 11th Conference on Retroviruses and Opportunistic Infections, February 10, 2004. San Francisco, California USA.
|
|
Nolan D. NNRTI Drugs and Their Role in Antiretroviral Therapy Merck Sharp and Dohme Symposium, December 06, 2003. Hang-Zhou, China.
|
|
Mallal SA. Hypersensitivity reactions to Ziagen The GlaxoSmithKline HIV/AIDS Teleconference Series - Ziagen simply extending HIV treatment options, June 28, 2003.
|
|
Mallal SA. HIV adaptation to HLA restricted immune responses Annual Harvard Medical School Centers for AIDS Research Symposium, June 16, 2003. Boston, USA.
|
|
Mallal S. Lipodystrophy- insights from epidemiology and the laboratory Australasian Society for HIV Medicine, October 26, 2002. Sydney, Australia.
|
|
Nolan D. Antiretroviral Therapy-Associated Lipodystrophy: From the Population Level to the Cellular Level Forum for Collaborative HIV Research, September 23, 2002. San Diego, California USA.
|
|
John M. Treatment Complications. HIV at the crossroads: applying the learnings for the future Content development meeting for instant access CD. AMA CME program, July 12, 2002. Barcelona, Spain.
|
|
John M. Long-term antiretroviral toxicities GSK satellite symposium, 14th World AIDS Congress, July 07, 2002. Barcelona, Spain.
|
|
Mallal SA. Mitochondrial toxicity 12th Clinical Care Options for HIV Symposium (U.S. CME accredited presentation and manuscript), April 27, 2002. Key Biscayne, Florida USA.
|
|
Mallal SA. Update on Risk Factors and Management of Lipodystrophy 3rd European Workshop on Lipodystrophy, April 25, 2002 to April 27, 2002 (April 25, 2002). Marbella, Spain.
|
|
Mallal SA . Understanding and Managing the Metabolic Complications of Anti-retroviral Therapy Cedar Sinai Hospital Grand Rounds (U.S. CME accredited presentation), April 20, 2002. Los Angeles, California USA.
|
|
Mallal S. Therapy for life: Understanding and managing long-term antiretroviral toxicity: selected summary of the 3rd International Workshop of Adverse Drug Reactions and Lipodystrophy in HIV GSK Symposium: 8th European Conference on Clinical Aspects and Treatment of HIV Infection, October 27, 2001. Athens, Greece.
|
|
Mallal SA. Metabolic abnormalities and long term side effects Nucleoside Expert Workshop, June 19, 2001. Vienna, Austria.
|
|
Mallal SA. Comparative long-term safety profiles of different first line options of treatment in HIV naïve patients GlaxoSmithKline symposium. XIth Symposium on HIV Infection, June 15, 2001. Toulon, France.
|
|
Mallal S. Satellite Symposium: Resistance and HIV therapy: dogma, data and dilemma and therapy failure - resistance and other factors 5th International Congress on Drug Therapy in HIV Infections, October 22, 2000. Glasgow, UK.
|
|
Kessler H, Powderly W, Mallal SA. Long-term complications: An interactive webcast. www.hivline.com , March 14, 2000.
|
|
Mallal S, Almeida C, Nolan D, Martin A. Abacavir hypersensitivity as a model for elucidating Class I restricted drug hypersensitivity 7th International Meeting of the International Society for the Study of Xenobiotics, August 29, 2004 to September 03, 2004. Vancouver, Canada.
|
|
Martin A, Cameron P, Nolan D, James I, Keller J, Phillips E, Mallal S. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*01 and higher CD4+ T cell counts. XV International AIDS Conference, July 11, 2004 to July 16, 2004. Bangkok, Thailand.
|
|
Nolan R, Martin A, Nolan D, Gaudieri S, Almeida C, Carvalho F, Witt C, Sayer D, Hermann S, Christiansen FT, Mallal S. Abacavir Hypersensitivity syndrome: clarifying genetic associations by including the presence of an abacavir specific immune response in diagnostic criteria 15th Annual Conference of the Australasian Society for HIV Medicine, October 22, 2003 to October 25, 2003. Cairns, Australia.
|
|
Martin AM, Nolan D, Gaudieri S, Almeida C, Nolan R, Herrmann S, James I, Christiansen FT, Mallal S. Association of HLA-B*5701 and HSP70-HOM with hypersensitivity to HIV reverse transcriptase inhibitor abacavir Pharmacogenomics, September 24, 2003 to September 28, 2003. Cambridge, UK.
|
|
Martin A, Nolan D, Gaudieri S, Almeida C, Carvalho F, Witt C, Nolan R, Herrmann S, Christiansen F, Mallal S. Updated experience of abacavir hypersensitivity genetic testing within the major histocompatability complex (MHC): addressing diagnostic precision and predictive value 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, July 08, 2003 to July 11, 2003. Paris, France.
|
|
Mallal S, Witt C, Martin AM, Masel G, Moore C, Sayer D, Castley C, Mamotte C, Nolan D, James I, Christiansen FT. The presence of HLA-B*5701, -DRB1*0701 and –DQ3 is highly predictive of hypersensitivity to the HIV reverse transcriptase inhibitor abacavir XIII International Congress of Histocompatability and Immunogenetics, May 18, 2002 to May 22, 2002. Seattle, Washington USA.
|
|
Hammond E, Nolan D, Martin A, Sayer D, Mallal S. A real-time PCR-based method for detecting mitochondrial DNA depletion: Assessment of assay precision Mitochondria and Pathogenesis, April 06, 2002 to April 12, 2002. Copper Mountain, Colorado USA.
|
|
Mallal S, Hammond E, Martin A, Nolan DA. Mitochondrial DNA depletion in adipocytes associated with NRTI treatment in HIV infected individuals 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, October 27, 2001 to October 31, 2002. Athens, Greece.
|
|
Hammond EL, Martin A, Taylor L, John M, Nolan DA, Mallal SA. Mitochondrial DNA depletion, assessed by real-time PCR-based quantitative assay in subcutaneous fat of HIV infected patients: Evidence for a role in the aetiology of fat wasting 4th International Conference on Nutrition and HIV infection, 2nd European Workshop on Lipodystrophy, April 19, 2001 to April 21, 2001. Cannes, France.
|
|
Gizzarelli L, Hammond E, Martin A, Nolan D, & Mallal SA. Level of heteroplasmy DNA detection in mtDNA using SSCP and DNA sequencing Australian Society for HIV Medicine, October 11, 2000 to October 14, 2000. Melbourne, Australia.
|
|
Witt C, Whiteway J, Rogers M, Martin A, Christiansen F . F Polymorphism of the KIR2DL4 receptor for HLA-G and its relationship to Pre-eclampsia 24th Annual Australian and South East Asian Tissue Typing Association Conference, November 30, 2000 to December 03, 2000. Perth, Australia.
|
|
Hammond E, Nolan D, McKinnon E, James I, Mallal S. Differential effects of nucleoside reverse transcriptase inhibitor (NRTI) regimens on adipocyte mitochondrial DNA depletion in HIV-infected patients 6th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, October 25, 2004 to October 28, 2004. Washington DC, USA.
|
|
Wong G, Kaul R, Shahabi K, Nolan D, Mallal S, Knowles S, Martin A, Shear N, Phillips E. Abacavir Hypersensitivity Syndrome: results of clinical, immunologic and genetic screening 6th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, October 25, 2004 to October 28, 2004. Washington DC, USA.
|
|
Gaudieri S, Freitas E, Moore C, Jeffrey G, Lucas M, John M, Cheng W, Herrmann S, D’Aquila R, Mallal S. Adaptation of Hepatitis C virus to HLA-restricted responses in HLA diverse populations 4th Australasian Hepatitis C Conference, August 31, 2004 to September 02, 2004. Canberra, Australia.
|
|
Mallal SA. HIV and Hepatitis C Adaptation to HLA-Restricted Immune Responses 16th Annual Conference of the Australasian Society for HIV Medicine, September 02, 2004 to September 04, 2004. Canberra, Australia.
|
|
Almeida C, Martin A, Nolan D, Mallal S. Increase in inflammatory cytokine levels in abacavir stimulated mono-nuclear cells from HIV infected patients with abacavir hypersensitivity 16th Annual Conference of the Australasian Society for HIV Medicine, September 02, 2004 to September 04, 2004. Canberra, Australia.
|
|
Herrmann S, McKinnon E, Mallal, S. Combining adherence monitoring with patient education in the Royal Perth Hospital Immunology Outpatient Clinic 16th Annual Conference of the Australasian Society for HIV Medicine, September 02, 2004 to September 04, 2004. Canberra, Australia.
|
|
Hammond E, Nolan D, James I, McKinnon E, Mallal S. Contribution of nucleoside analogue reverse transcriptase inhibitor therapy to lipoatrophy in HIV infected patients: a model of drug induced mitochondrial toxicity, Mitochondrial Medicine, August 04, 2004 to August 08, 2004. Pittsburgh, Pennsylvania.
|
|
McKinnon E, James I, Mallal S. Assessment of virological control in patients with HIV undergoing HAART International Workshop on HIV Observational Databases, March 25, 2004 to March 28, 2004. Montreux, Switzerland.
|
|
Martin A, Almeida C, Nolan D, Gaudieri S, James I, Christiansen F, Purcell A, McCluskey J, Mallal S. Carriage of HLA-B*5701 and a Haplotypic Hsp70-Hom Variant is Associated with a Class I MHC-Restricted Hypersensitivity Response to Abacavir 11th Conference on Retroviruses and Opportunistic Infections, February 08, 2004 to February 11, 2004. San Francisco, California USA.
|
|
McKinnon EJ, James IR, Mallal S. Response to HAART: Host genetic associations Annual North American Observational Database Meeting, November 13, 2003 to November 13, 2003. Washington, USA.
|
|
Nolan R, Martin AM, Nolan D, Gaudieri S, Almeida C, Carvalho F, Witt C, Sayer D, Herrmann S, Christiansen FT, Mallal S. Abacavir Hypersensitivity Syndrome: Clarifying genetic associations by including the presence of an abacavir specific immune response in diagnostic criteria 15th Annual Conference of the Australian Society for HIV Medicine, October 22, 2003 to October 25, 2003. Cairns, Australia.
|
|
Christiansen FT, Gaudieri S, Moore CB, Martin A, Nolan D, James IR, McKinnon E, De Santis D, Witt CS, Mallal SA. The immune response to HIV: The interplay between virus and host genetic factors British Society for Immunology, December 02, 2003 to December 05, 2003. Harrogate, UK.
|
|
Martin AM, Nolan D, Gaudieri S, Almeida C, Nolan R, Herrmann S, James I, Christiansen FT, Mallal S. Association of HLA-B*5701 and Hsp70-Hom with hypersensitivity to HIV reverse transcriptase inhibitor abacavir Pharmacogenomics, September 24, 2003 to September 28, 2003. Cambridge, UK.
|
|
Christiansen F. NK receptor genes are predictors of HIV progression The 7th Asia-Oceania Histocompatibility Workshop and Conference, September 16, 2003 to September 19, 2003. Karuizawa, Japan.
|
|
Mallal S. Vaccine Development: Can Host HLA Diversity be Exploited to Overcome the Problems of HIV Diversity? AIDS Vaccine 2003 (Program and Abstracts: Plenary Session 15), September 18, 2003 to September 21, 2003. New York City, USA.
|
|
Mallal SA. The toxicogenomics of abacavir hypersensitivity Symposium:The Future of Toxicogenomics in Antimicrobial Drug Development and Approval at the 43rd Annual Interscience Conference on Antimicrobial Agen, September 14, 2003 to September 17, 2003. Chicago, Illinois.
|
|
Mallal SA. Understanding mitochondrial toxicity, prevention, monitoring and management 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, September 14, 2003 to September 17, 2003. Chicago, Illinois USA.
|
|
Hammond E, Nolan D, McKinnon E, James I, Mallal S. Subcutaneous fat tissue mitochondrial DNA depletion and adipose toxicity are strongly associated with nucleoside reverse transcriptase inhibitor (NRTI) therapy in HIV-infected patients 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, July 08, 2003 to July 11, 2003. Paris, France.
|
|
James I, Nolan D, McKinnon E, Hammond E, Mallal S. Contribution of nucleoside analogue reverse transcriptase inhibitor therapy to lipodystrophy: trends in subcutaneous fat wasting and association with mitochondrial DNA depletion 7th International Workshop on HIV Observational Databases, March 28, 2003 to March 30, 2003. Fiuggi, Italy.
|
|
McKinnon E, Fusco J, John M, Fusco G, Becker S, James I, Mallal S. Assessment of global virological response to first HAART via convolutions - a CHORUS/WAHIV collaborative study 7th International Workshop on HIV Observational Databases, March 28, 2003 to March 30, 2003. Fiuggi, Italy.
|
|
Martin A, Gaudieri S, Witt C, Nolan D, Christiansen F, Mallal S. Mapping of Genetic Susceptibility to Abacavir Hypersensitivity 10th Conference on Retroviruses and Opportunistic Infections, February 10, 2003 to February 14, 2003. Boston, Massachusetts USA.
|
|
Hammond E, Nolan D, James I, McKinnon E, White A, Mallal S. Evidence of toxicity in adipose tissue of HIV infected patients correlates with NRTI associated mtDNA depletion 10th Conference on Retroviruses and Opportunistic Infections, February 10, 2003 to February 14, 2003. Boston, Massachusetts USA.
|
|
Cherry C, Nolan D, Hammond E, Gahan M, James I, McKinnon E, McArthur J, Mallal S, Wesselingh S. Associations between antiretroviral treatments and tissue mitochondrial DNA deletion in two cohorts of HIV-infected subjects 10th Conference on Retroviruses and Opportunistic Infections, February 10, 2003 to February 14, 2003. Boston, Massachusetts USA.
|
|
Nolan D, James I, McKinnon E, Mallal S. Effect of stavudine, zidovudine and HIV protease inhibitor therapy on subcutaneous leg fat wasting in HIV-infected males – a longitudinal study 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, September 22, 2002 to September 25, 2002. San Diego, California USA.
|
|
Hill A, James I, McKinnon E, Law M. Statistical Power to detect drug toxicity in HIV clinical trials 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, September 22, 2002 to September 25, 2002. San Diego, California, USA.
|
|
James J, McKinnon E, Mallal S. Comparison of rates of progression in HIV observational cohorts 6th International Workshop on HIV Observational Databases, March 21, 2002 to March 22, 2002. Sintra, Portugal.
|
|
McKinnon E, John M, James I, Mallal S. Effect of baseline CD4 on virological response to first HAART 6th International Workshop on HIV Observational Databases, March 21, 2002 to March 22, 2002. Sintra, Portugal.
|
|
McKinnon E, John M, James I, Mallal, S. Progressive matching in HIV observational studies 6th International Workshop on HIV Observational Databases, March 21, 2002 to March 22, 2002. Sintra, Portugal.
|
|
John M, Mallal S. HIV adaptation to genetic polymorphisms of the host 10th Conference on Retroviruses and Opportunistic Infections, February 10, 2003 to February 14, 2003. Boston, Massachusetts USA.
|
|
John M, James I, McKinnon E, Nolan D, Herrmann S, Cain A, Martinez OP, White A, Mallal S. A randomised, controlled, open label study of revision of antiretroviral regimens containing stavudine (d4T) and/or a protease inhibitor (PI) to zidovudine (ZDV)/lamiduvine (3TC)/abacavir (ABC) to prevent or reverse lipoatrophy: 48 week data 9th Conference on Retroviruses and Opportunistic Infections, February 24, 2002 to February 28, 2002. Seattle, Washington USA.
|
|
Martinez OP, Nolan D, Hammond E, Martin A, Herrmann S, McKinnon E. Mitochondrial DNA depletion and abnormal mitochondrial morphology in subcutaneous fat of NRTI-treated HIV-infected patients 1st IAS Conference on Pathogenesis and Treatment of HIV Infection, July 08, 2001 to July 11, 2001. Buenos Aires, Argentina.
|
|
Moore C, John M, James I, Mallal SA. Characteristic Mutations in HIV-1 Reverse Transcriptase Sequence Encoding HLA class I restricted CTL epitopes: Evidence of HIV-1 CTL Escape at a Population level 24th Annual Australian and South East Asian Tissue Typing Association Conference, November 30, 2000 to December 03, 2000. Perth, Australia.
|
|
John M, Moore C, James I, Mallal S. Characteristic non-synonymous mutation in HIV reverse transcriptase sequence encoding an HLA B7 restricted CTL epitope is associated with increased viral load 8th Conference on Retroviruses & Opportunistic Infections, February 04, 2001 to February 08, 2001. Chicago, Illinois USA.
|
|
James I, Moore C, John M, Nolan D, McKinnon E, Mallal, S. Effect of HAART on subcutaneous fat in HIV-infected males - a longitudinal study 5th International Workshop on HIV Observational Databases, April 26, 2001 to April 27, 2001. Monte Carlo.
|
|
John M, Moore C, James I, Mallal, S. Selection of immune escape mutation in HIV-1 is evident at a population level Australian Society for HIV Medicine (ASHM), October 04, 2001 to October 07, 2001. Melbourne, Australia.
|
|
Mallal S, Masel G, Castley A, Mamotte C, Moore C, Witt C, Sayer D, Martinez OP, John M, Nolan D. Tumour Necrosis Factor-alpha (TNFa) promotor region gene polymorphisms in HIV-1 infected patients with Abacavir hypersensitivity (ABC HSR) reactions 9th Conference on Retroviruses and Opportunistic Infections, February 24, 2002 to February 28, 2002. Seattle, Washington USA.
|
|
Moore C, John M, James I, Mallal S. The influence of host HLA on antiretroviral drug resistance mutation in HIV-1 9th Conference on Retroviruses and Opportunistic Infections, February 24, 2002 to February 28, 2002. Seattle, Washington, USA.
|
|
Mallal S, Witt C, Martin AM, Masel G, Moore C, Sayer D, Castley C, Mamotte C, Nolan D, James I, Christiansen FT. The presence of HLA-B*5701, -DRB1*0701 and -DQ3 is highly predictive of hypersensitivity to the HIV reverse transcriptase inhibitor abacavir XIII International Congress of Histocompatability and Immunogenetics, May 18, 2002 to May 22, 2002. Seattle, Washington USA.
|
|
Nolan D, Moore C, Castley A, Sayer D, Mamotte C, John M, James I, Mallal S. Tumour necrosis factor-alpha gene - 238G/A promotor polymorphism associated with more rapid onset of lipodystrophy 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, September 22, 2002 to September 25, 2002. San Diego, California USA.
|
|
John M, Moore C, James I, Mallal S. Immune escape mutations in HIV-1 at a population level GSK Observational Cohorts Meeting, November 06, 2002 to November 07, 2002. Washington, USA.
|
|
Christiansen F, Moore C, De Santis D, Gaudieri S, Witt C. HLA and NK receptor genes in HIV progression 17th European Histocompatibility Conference & 11th Annual Meeting, German Society of Immunogenetics, May 06, 2003 to May 09, 2003. Baden-Baden, Germany.
|
|
Mallal S, Moore C, Carvalho F, Patterson A, Liu C, Goodridge D, Sayer D, James I, John M. HIV adaptation to HLA-restricted immune responses - implications for vaccine design and evaluation 10th Conference on Retroviruses and Opportunistic Infections, February 10, 2003 to February 14, 2003. Boston, Massachusetts USA.
|
|
John M, Moore C, James I, Nolan D, Upton R, McKinnon E, Mallal SA. Relative contributions of NRTIs, NNRTIs and PIs to chronic asymptomatic lactic acidemia European Symposium on Lipodystrophy and HIV infection, May 24, 2000 to May 25, 2000. Marrakesh, Morocco.
|
|
John M, Moore C, James I, Nolan D, Upton R, Mallal SA. Predictors of lactic acidemia in the WA HIV Cohort Fourth International Cohorts Meeting, March 30, 2000 to March 31, 2000. Marbella, Spain.
|
|
John M, Moore C, James I, Nolan D, Mallal SA. Predictors of response to antiretroviral therapy in the WA HIV Cohort Fourth International Cohorts Meeting, March 30, 2000 to March 31, 2000. Marbella, Spain.
|
|
Moore C, John M, Mallal SA. Costs associated with management of lipodystrophy syndrome Fourth International Cohorts Meeting, March 30, 2000 to March 31, 2000. Marbella, Spain.
|
|
Nolan D, Upton R, James I, McKinnon E, John M, Mallal S. Longitudinal analysis of bone mineral density (BMD) in HIV infected patients treated with HAART 2nd International Workshop on Adverse Drug reactions and lipodystrophy in HIV, September 13, 2000 to September 15, 2000. Toronto, Canada.
|
|
French MA, Stone SF, Keane NM, John M, Price P . HIV-infected patients who had immune restoration disease after highly active antiretroviral therapy (HAART) have distinct HLA and cytokine profiles XIII International AIDS Conference, July 09, 2000 to July 14, 2000. Durban, South Africa.
|
|
Petoumenos K, on behalf of The Australian HIV Observational Database. Use of combination antiretroviral treatments in Australia, 1997-2000 Australian Society for HIV Medicine, October 12, 2000 to October 14, 2000. Melbourne, Australia.
|
|
Law MG on behalf of The Australian HIV Observational Database. Rates of change of combination antiretroviral treatments in Australia, 1997-2000 5th International Congress on Drug Therapy in HIV Infection, October 22, 2000 to October 26, 2000. Glasgow, UK.
|
|
Martin AM, Almeida C, Nolan D, Mallal S. TLR2 and CD14 receptors are essential for abacavir induced HSP70 signalling and dendritic cell activation ANS Apoptosis and Immunity 2005, May 31, 2005. Cairns, Australia.
|
|
James I, McKinnon E, John M, Mallal S. Association of HLA-Bw4 with post-HAART outcomes 9th International Workshop on HIV Observational Databases, April 21, 2005 to April 22, 2005. Budapest, Hungary.
|
|
Pace CS, Nolan DA, Mallal SA. Characterisation of the human deoxythymidylate kinase (dTMPK) gene and its influence on in vivo haematological response to AZT therapy. 7th International Workshop on Clinical Pharmacology of HIV Therapy, April 20, 2006 to April 22, 2006 (April 21, 2006). Lisbon, Portugal.
Abstract
|
|
Pace C, Keller J, Nolan D, James I, Gaudieri S, Moore C, Mallal S. Population level analysis of HIV-1 hypermutation and its relationship with APOBEC3G and vif genetic variation. The Merck Sharp & Dohme Young Investigators Meeting 2005, 2nd Place, November 09, 2005. Perth, WA, Australia.
Abstract
Video
|
|
Mallal S. Role of NRTI-induced adipocyte mtDNA depletion of lipoatrophy Mitochondrial Toxicity and HIV Infection: understanding the pathogenesis for a therapeutic approach, May 19, 2005 to May 21, 2005 (May 20, 2005). Modena, Italy.
|
|
Allen T, Altfeld M, Geer S, Kalife E, Moore C, O’Sullivan K, DeSouza, Kaufmann D, Lahaie M, Reyor L, Brander C, Jessen H, Rosenberg E, Mallal S, Walker B. Stereotypic Escape from CD8+ T Cell Responses Represents a Major Driving Force of HIV-1 Sequence Diversity and Reveals Constraints on HIV-1 Evolution 12th Conference on Retroviruses and Opportunistic Infections, February 22, 2005 to February 25, 2005 (February 22, 2005). Boston, USA.
Abstract
|
|
Pace C, Martin A, Hammond E, Mamotte C, Nolan D, Mallal S . Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV+ HAART recipients. The Merck Sharp & Dohme young Investigators Day 2004, 2nd Place, November 10, 2004. Perth, WA, Australia.
Abstract
Video
|
|
Wong G, Kaul R, Shahabi K, Nolan D, Mallal S, Knowles S, Martin A, Shear N, Phillips E. Abacavir Hypersensitivity Syndrome: results of clinical, immunologic and genetic screening Lipodystrophy Workshop, , October 30, 2004. Washington DC, USA.
|
|
Almeida C, Martin A, Nolan D, Mallal S. Increase in inflammatory cytokine levels in abacavir stimulated mononuclear cells in HIV infected patients with abacavir hypersensitivity ASHM, Canberra, September 10, 2004.
|
|
Christiansen FT, Gaudieri S, De Santis D, McKinnon E, Moore C, Nolan D, Mallal S. NK receptor haplotypes and HLA as predictors of HIV-1 progression NK2004 Workshop, April 24, 2004 to April 28, 2004 (April 24, 2004). Noordwijkerhout, The Netherlands.
|
|
Christiansen FT, Gaudieri S, Moore CB, Martin A, Nolan D, James IR, McKinnon E, De Santis D, Witt CS, Mallal SA. The immune response to HIV: The interplay between virus and host genetic factors British Society for Immunology, December 02, 2003 to December 05, 2003 (December 02, 2003). Harrogate, UK.
|
|
Christiansen F, Gaudieri S, De Santis D, Moore C, Witt C, James I, Mallal S. NK receptor genes are predictors of HIV progression ASHI, October 28, 2003 to November 01, 2003 (October 28, 2003). Miami Beach, Florida.
|
|
John M, Moore C B, James IR, Christiansen FT, Witt CS, Mallal SA. Putative Immune Escape Mutations in HIV-1 Sequence: The Influence of HLA Class I and II Alleles in a Host Population on Viral Evolution 13th International HLA Congress, May 14, 2002 to May 18, 2002 (May 14, 2002). Seattle, Washington.
|
|
Nolan D, Hammond E, Martin A, Metcalf C, Latham B, John M, Mallal, S. NRTI therapy is associated with mitochondrial DNA depletion, increased mitochondrial biogenesis and subcutaneous fat wasting in HIV infected patients HIV Pathogenesis and Treatment, July 08, 2001. Buenos Aires, Argentina.
|
|
Mallal SA. Comparative long-term safety profiles of different first line options of treatment in HIV naïve patients XIth Symposium on HIV Infection, GlaxoSmithKline symposium, June 15, 2001.
|
|
White A, John M, Moore C, James IR, Nolan D, Mallal SA. Raised lactate levels are common and may be predictive of subcutaneous fat wasting 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, September 13, 2000 to September 15, 2000 (September 01, 2000). Toronto, Canada.
|
|
Mallal SA, Moore C, John M, James I, Nolan D, Sayer D, Witt C. Characteristic changes in HIV reverse transcriptase sequence at sites encoding known CTL epitopes at a population level XIII International AIDS Conference, July 09, 2000 to July 14, 2000 (July 09, 2000). Durban, South Africa.
|
|
Martin A, Almeida C, Nolan D, Gaudieri S, James I, Christiansen FT, Purcell AW, McCluskey J, Mallal SA. . Carriage of HLA-B*5701 and a Haplotypic Hsp70-Hom Variant is Associated With a Class I MHC-Restricted Hypersensitivity Response to Abacavir 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 08, 2004 to February 11, 2004.
|
|
Martin A, Gaudieri S, Witt C, Nolan D, Christiansen F, & Mallal S. Mapping of Genetic Susceptibility to Abacavir Hypersensitivity 10th Conference on Retroviruses and Opportunistic Infections, February 10, 2003 to February 14, 2003. Boston, MA, USA.
|
|
Martinez OP, Nolan D, Hammond E, Martin A, Herrmann, S McKinnon, E. Mitochondrial DNA depletion and abnormal mitochondrial morphology in subcutaneous fat of NRTI-treated HIV-infected patients 1st IAS Conference on Pathogenesis and Treatment of HIV Infection, July 08, 2001 to July 11, 2001. Buenos Aires, Argentina.
|
|
Gaudieri S, Freitas E, Moore C, Lucas M, Jeffrey G, Cheng W, John M, Mallal S. Adaptation of Hepatitis C virus to HLA-restricted responses in HLA diverse populations 11th International Symposium on Hepatitis C and Related Diseases, October 03, 2004 to October 07, 2004. Heidelberg Germany.
|
|
Lucas M, Northfield J, Young N, Lauer G, Walker B, Klenerman, P. HCV specific CD8+ T- cells display a novel pattern of expression of NK inhibitory molecules 11th International Symposium on Hepatitis C and Related Diseases, October 03, 2004 to October 07, 2004. Heidelberg Germany.
|
|
Herrmann S, Hyland N, Coombs A, Turner K, Duncan F, McKinnon E, James I, Martinez OP, French M, Mallal S. Adherence to antiretroviral therapy in the WA HIV Cohort 15th Annual Conference of the Australian Society for HIV Medicine, October 22, 2003 to October 25, 2003. Cairns, Australia.
|
|
James I, Nolan D, Hammond E, McKinnon E, Mallal S. Longitudinal effects on subcutaneous fat mass of initiating or switching stavudine and zidovudine-based antiretroviral therapy 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, July 08, 2003 to July 11, 2003. Paris, France.
|
|
Hammond E, Nolan D, McKinnon E, Mallal, S. Lack of evidence of mitochondrial DNA depletion in peripheral blood white cells after three to 15 months of HAART XIV International AIDS Conference, July 07, 2002 to July 12, 2002. Barcelona, Spain.
|
|
Mallal SA, Nolan DA, John M, Chong D, Metcalf C, Latham B. Light and electron microscopy findings in subcutaneous fat in antiretroviral treated and naïve HIV-infected patients XIII International AIDS Conference, July 09, 2000 to July 14, 2000. Durban, South Africa.
|
|
Jojic V, Jojic N, Moore C, John M, Mallal S. HLA-driven optimisation of an HIV vaccine immunogen using epitomes 12th Conference on Retroviruses and Opportunistic Infections, February 22, 2002 to February 25, 2005. Boston, Massachusetts USA.
|
|
Martin A, Almeida CA, Nolan D, Cameron P, James I, Purcell T, McCluskey J, Phillips E, Mallal S. Abacavir stimulates Hsp70 redistribution in antigen presenting cells of patients with hypersensitivity: association with type-1 alcohol dehydrogenase activity 12th Conference on Retroviruses and Opportunistic Infections, February 22, 2002 to February 25, 2005. Boston, Massachusetts USA.
|
|
Park L, Mallal S. HLA-restricted immune responses have driven the evolution of HIV-1 clades 12th Conference on Retroviruses and Opportunistic Infections, February 22, 2005 to February 25, 2005. Boston, Massachusetts USA.
|
|
McKinnon E, Lucas M, French M, James I, Mallal S. Differential influence of age on CD4 T-cell response to HAART 9th International Workshop on HIV Observational Databases, April 21, 2005 to April 22, 2005. Budapest, Hungary.
Abstract
|
|
Gaudieri S, Moore C, D’Aquilla R, Dietrich D, Lucas M, Klenerman P, John M, Freitas E, Jefferies G, Mallal S. CTL Hepatitis C Virus Escape Mutants in HLA-Diverse Populations 10th International Meeting on Hepatitis C Virus and Related Viruses, December 02, 2003 to December 06, 2003. Kyoto, Japan.
|
|
Pace C, Martin A, Hammond E, Mamotte C, Nolan D & Mallal S. Mitochondrial Proliferation, DNA Depletion, and Adipocyte Differentiation and Phenotype in Subcutaneous Adipose Tissue of HIV+, HAART Recipients. 10th Conference on Retroviruses & Opportunistic Infections, February 10, 2003 to February 14, 2003. Boston, Massachusetts USA.
Abstract
|
|
Pace C, Nolan D, Keller J, Gaudieri S, Carvalho F, Moore C, Freitas E, Sutton K, Mallal S. Analysis of HIV-1 G-->A Hypermutation and it's Relationship with APOBEC3G and Vif Genetic Variation In Vivo. 12th Conference on Retroviruses & Opportunistic Infections, February 22, 2005 to February 25, 2005 (February 22, 2005). Boston, Massachusetts USA.
Abstract
|
|
Mallal S, Moore C, James IR, Sayer D, Witt C, Christiansen FT, French MA. Class I MHC associated non-synonymous mutations of HIV sequences- possible selection of CTL escape mutations at a population level? A Keystone Symposia: AIDS Pathogenesis, January 07, 1999 to January 13, 1999 (January 08, 1999). Colorado, USA.
Abstract
|
|
|
|
